| 2019-05-22 08:36:52|
ONCS 08:36 05/22 05/22/19
OncoSec reports interim data from Keynote-890 study of breast cancer combination
OncoSec announced interim data from Keynote-890, an ongoing Phase 2 study of Tavo - intratumoral IL-12 - in combination with Keytruda in patients with heavily pretreated, metastatic, chemotherapy refractory triple negative breast cancer, or mTNBC. Patients who previously failed an average of 3.5 prior lines of chemotherapy were enrolled in Keynote-890 to evaluate if the addition of Tavo could provide meaningful clinical activity when combined with Keytruda. Heavily pretreated patients with refractory mTNBC showed a rapid tumor reduction of 20% or greater at the initial 3-month evaluation in the first five of 10 patients. Two patients had a partial response, one with a 66% tumor reduction, including a significant reduction of liver lesions, and four patients had stable disease, three of which reported a 20% or greater tumor reduction. These preliminary findings, when compared to the results of Keynote-086, which demonstrated a 5.3% response rate in mTNBC patients treated with Keytruda monotherapy, suggest Tavo's ability to unlock Keytruda's potential anti-cancer efficacy in this patient population. Four of the six patients who experienced tumor reductions have an ongoing response as of May 9. Of the four patients who progressed following treatment, two received only one cycle of combination treatment prior to rapid clinical deterioration. Treatment was very well-tolerated, with only three patients reporting Grade 1 Tavo-related adverse events. No Tavo-related Grade 2 or above AE's/SAE's were reported. The company has enrolled over half of the targeted enrollment of 25 patients, and expects to complete enrollment and present the clinical data at the San Antonio Breast Cancer Symposium later this year.